Early breast cancer treatment before surgery
For some people with early breast cancer, it may be beneficial to start treatment before having surgery. This is called neoadjuvant treatment.
Prior to surgery, PERJETA is approved for use in combination with Herceptin® (trastuzumab) and chemotherapy in people with HER2+, locally advanced, inflammatory, or early stage breast cancer (tumor greater than 2 cm in diameter or node-positive). PERJETA should be used as part of a complete treatment regimen for early breast cancer.
One of the goals of neoadjuvant treatment for early breast cancer is to help reduce or get rid of cancer cells before surgery.
Keep in mind that not all cancers respond to neoadjuvant treatment.
In addition, some people may experience serious or common side effects
while receiving neoadjuvant treatment.
Starting PERJETA-based therapy before surgery
People who are eligible may receive 3-6 cycles (9-18 weeks) of PERJETA and Herceptin before surgery.
*Adjuvant treatment may vary.
†Unless side effects become too difficult to manage, or the cancer comes back sooner.
You will also be given chemotherapy, but the dosing schedule and number of cycles will depend on which type of chemotherapy you receive.
Cycle: A course of treatment that is repeated on a regular schedule with periods of rest in between. For example, PERJETA + Herceptin is given once every 3 weeks. That is one cycle.
Side effects may occur with PERJETA
What are the most serious side effects of PERJETA?
Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.
PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).
What are other possible serious side effects of PERJETA?
PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA. Possible serious and sometimes fatal side effects of PERJETA include infusion-related reactions and severe allergic reactions (hypersensitivity reactions/anaphylaxis).
See additional Important Safety Information below.
How your doctor will tell if your cancer is responding to neoadjuvant treatment
Breast tissue and nodes will be removed during surgery. A pathologist will then look at them to see if cancer cells can be detected. If none are present, this is called a pathological complete response (pCR). pCR is not a cure.
In a clinical trial with certain people with HER2+ early breast cancer, neoadjuvant PERJETA + Herceptin + docetaxel was compared to Herceptin + docetaxel.
Almost twice as many people who got PERJETA + Herceptin-based therapy before surgery had no detectable cancer cells in the lymph nodes and breast tissue removed during surgery (39.3%), compared with people who received the other treatment (21.5%).